ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$18.75 USD
-0.39 (-2.04%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $18.76 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Cash flow Statements
Fiscal Year End for ACADIA Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -61.29 | -215.98 | -167.87 | -281.58 | -235.26 |
Depreciation/Amortization & Depletion | -1.98 | -0.71 | 5.75 | 4.40 | -0.85 |
Net Change from Assets/Liabilities | 18.13 | 37.99 | -24.82 | 11.04 | 3.71 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 61.84 | 64.66 | 61.29 | 129.98 | 81.27 |
Net Cash From Operating Activities | 16.70 | -114.04 | -125.66 | -136.17 | -151.13 |
Property & Equipment | -0.05 | 0.00 | -1.12 | -7.59 | -1.13 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 72.05 | 73.24 | -69.98 | 200.10 | -164.71 |
Other Investing Activities | -40.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 32.00 | 73.24 | -71.10 | 192.51 | -165.84 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 25.13 | 8.20 | 18.16 | 81.00 | 371.85 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 25.13 | 8.20 | 18.16 | 81.00 | 371.85 |
Effect of Exchange Rate Changes | -0.02 | 0.01 | 0.01 | -0.01 | 0.00 |
Net Change In Cash & Equivalents | 73.81 | -32.59 | -178.59 | 137.33 | 54.88 |
Cash at Beginning of Period | 120.62 | 153.21 | 331.80 | 194.47 | 139.58 |
Cash at End of Period | 194.43 | 120.62 | 153.21 | 331.80 | 194.47 |
Diluted Net EPS | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 |
Fiscal Year End for ACADIA Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 16.56 | -61.29 | -107.08 | -41.91 |
Depreciation/Amortization & Depletion | NA | 3.74 | -1.98 | -1.84 | -1.57 |
Net Change from Assets/Liabilities | NA | -5.97 | 18.13 | -3.58 | 6.98 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 14.75 | 61.84 | 43.81 | 26.76 |
Net Cash From Operating Activities | NA | 29.08 | 16.70 | -68.69 | -9.73 |
Property & Equipment | NA | 0.00 | -0.05 | -0.05 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -14.04 | 72.05 | 72.39 | 38.24 |
Other Investing Activities | NA | 0.00 | -40.00 | -40.00 | -40.00 |
Net Cash from Investing Activities | NA | -14.04 | 32.00 | 32.35 | -1.77 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.04 | 25.13 | 19.70 | 6.94 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 1.04 | 25.13 | 19.70 | 6.94 |
Effect of Exchange Rate Changes | NA | 0.01 | -0.02 | -0.01 | 0.00 |
Net Change In Cash & Equivalents | NA | 16.09 | 73.81 | -16.65 | -4.56 |
Cash at Beginning of Period | NA | 194.43 | 120.62 | 120.62 | 120.62 |
Cash at End of Period | NA | 210.52 | 194.43 | 103.96 | 116.06 |
Diluted Net EPS | NA | 0.10 | 0.29 | -0.40 | 0.01 |